Apaziquone

Summary

Apaziquone (CHEMBL73822) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including urinary bladder neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 7
• Chemistry: 288.3 Da · C15H16N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL73822
Name	Apaziquone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5813717
Molecular formula	C15H16N2O4
Molecular weight	288.3
InChIKey	MXPOCMVWFLDDLZ-NSCUHMNNSA-N

SMILES: CN1C(=C(C2=C1C(=O)C=C(C2=O)N3CC3)CO)/C=C/CO

IUPAC name: 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione

Also known as: Apazicuona, Apaziquone, EO-9, EO9, Eoquin, NOR-701, NSC-382456, NSC-382459, Qapzola, SID470867, APAZIQUONE

Patent coverage: 584 distinct patent families (1,547 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
urinary bladder neoplasm	3	MONDO:0004987	EFO:0000294

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	6
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00461591	PHASE3	COMPLETED	Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
NCT00598806	PHASE3	COMPLETED	Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)
NCT01410565	PHASE3	TERMINATED	Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
NCT01469221	PHASE3	TERMINATED	Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
NCT02563561	PHASE3	TERMINATED	A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)
NCT03224182	PHASE3	TERMINATED	A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)
NCT00141531	PHASE2	COMPLETED	Phase II Trial of EOquin in High-risk Superficial Bladder Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).